Latest news with #Nice
Daily Mail
14 hours ago
- Daily Mail
I'm a female solo traveller - the country where I felt the most unsafe is a European bucket-list destination
A solo travel content creator has shared her honest views on where she feels unsafe as a woman – and one of her picks is a hugely popular European destination. Savanna Crowell, who runs the @solowithsav Tiktok account, describes herself as 'your go-to solo travel girlie'. In a recent video that has been viewed almost 500,000 times, the New York-based traveller revealed three places where she didn't feel safe. Her first red-flagged destination is France – the world's most visited country, with 102 million international tourists arriving in 2024. She told her 54,000 followers she'd 'had a few uncomfortable situations in the country', facing problems in a number of locations. 'On my first solo trip to Paris, I almost got scammed by the 'petition scammers' at the Louvre,' she said. Petition scammers often pose as charity workers or petitioners who might speak to tourists about worthy causes – before putting pressure on them to hand over money. 'When I tried to get out of it they became very aggressive… thankfully I was able to get out of it because there were a lot of other people around me. Savanna felt unsafe in France, the country that saw the most visitors in 2024 Savanna also had issues in Nice, a beautiful city on the French Riviera. While she was walking along a street by herself, a man 'popped out of the bush with a pointy stick in his hand'. Savanna goes on to say he 'started chasing me down the road, ended up throwing the stick at me and laughing'. Despite the popularity of France, a number of other holidaymakers in the comments section voiced their unhappy experiences in the country. 'Facts! A man followed me into the girls' restroom in Paris and there is a section of Nice super unsafe for women,' wrote Alexandra Priscilla. Another user shared a story of a trip to Nice with her husband that saw a simple stop in a pharmacy turn scary. 'He bought sunscreen and sunglasses and we walked out and on the way out were stopped by a guard and we were taken to a back room where they had accused us of stealing,' said @katieter01. 'They went through our bags and pockets and were threatening us with the police but wouldn't even tell us what they thought we stole. 'We did not steal anything and eventually another manager came by and said we can leave but it was super scary we were held in this room with guards for a while.' One person said she 'had a dude harass me in France', though another wrote they 'felt super safe in France traveling solo'. The second country that left Savanna feeling unsafe was Mexico, a place she admits she loves travelling around. 'I did have an uncomfortable situation with a man once at a beach,' she said. I was sitting, minding my own business, when he came up, approached me, but his towel directly next to mine and started asking me very uncomfortable questions – like where I'm staying, how long I'm going to be staying. 'Just very intrusive questions where my gut was telling me 'I need to get out of this situation'.' Savanna waited until the man went into the ocean before grabbing all of her belongings and ran from the shore. Her third and final country to warn about is Nicaragua, the Central American nation between the Pacific Ocean and Caribbean Sea. Nicaragua gets the unfortunate title of country where Savanna received the most catcalls It was unfortunately the place where the content creator experienced the most catcalling. 'It seemed everywhere I went on the street, if a man went by he had to say something or make a noise – something that made me feel uncomfortable.' It was so bad, Savanna said she only wanted to walk on very busy streets. Despite her experiences, the travel enthusiasts admitted she would return to all of those countries.
Yahoo
15 hours ago
- Health
- Yahoo
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Scientists are to examine whether drugs that are already in use could be repurposed to treat the symptoms of both Alzheimer's disease and Parkinson's in a new collaboration which aims to discover novel treatments at pace. Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
Yahoo
20 hours ago
- Entertainment
- Yahoo
Weekly Young and the Restless Spoilers June 16-20: The Dumas Debut Is Here, Who's About to Get Burned?
The Young and the Restless spoilers for June 16-20 focus on the party that Dumas's reveal party in Nice, France. So it's Bon Voyage to many of Genoa City's biggest heavy hitters and others who managed to score an invite using their connections. We're talking about you two, Phyllis and Audra. Genoa City has been so laser-focused on all things Dumas, it's about time for the man to reveal himself. Next week, he has put together a big shindig in the south of France where the Newmans, Abbotts, Winters, and a few others will gather to hopefully get a peek at this person…FINALLY. Victor (Eric Braeden), of course, says he knows who Dumas is. He's 100% sure it's not Tucker McCall. What does he know? Well, expect Victor to reveal details about Dumas. Meanwhile, Billy (Jason Thompson) puts his plan in motion. What's that plan again? To make sure that everything goes badly for Victor? And if things get dramatic, hightail it out of there? In other news, Phyllis (Michelle Stafford) makes herself at home. This is one of her superpowers. Dumas might not ever get her to leave. As for Jack (Peter Bergman) and Diane (Susan Walters), they have second thoughts about meeting the mysterious Dumas. Their son, on the other hand, might not have a good business trip. If Kyle (Michael Mealor) falls into a trap, they mean Audra's (Zuleyka Silver) trap, right? Will Kyle have a relationship with Claire (Hayley Erin) to go back to after this trip? Finally, at the end of next week, Aristotle Dumas reveals himself to his guests. Will Billy Flynn be playing Dumas? The teasers suggest that Amanda's (Mishael Morgan) real connection to him is exposed. Is she more than his attorney? What is the nature of their relationship? READ THIS: Here's what else is coming up next on Y&R. Back in Genoa City, Tessa (Cait Fairbanks) loses patience with Mariah (Camryn Grimes). Do you blame her? Sure, Mariah has started opening up to her wife. But she's holding back something that could potentially be huge. She has to know how frustrating that is for her wife. Elsewhere, Nate (Sean Dominic) puts Holden (Nathan Owens) on notice. Right now, Holden is fighting joining Winters because he thinks Damian (Jermaine Rivers) has left him behind in favor of his new family. Nate could set the guy straight by the time Damian gets back from the south of France. Could Holden end up working for Winters? Victor, Nikki (Melody Thomas Scott), and Nick (Josh Morrow) are attending the Dumas party. And Victoria (Amelia Heinle) and Claire and taking care of Cole (J. Eddie Peck). Look for Adam (Mark Gorrmsn) and Chelsea (Melissa Claire Egan) to mix business with pleasure.
Yahoo
a day ago
- Business
- Yahoo
Wall Street Analysts See Nice (NICE) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Nice (NICE). Nice currently has an average brokerage recommendation (ABR) of 1.56, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 16 brokerage firms. An ABR of 1.56 approximates between Strong Buy and Buy. Of the 16 recommendations that derive the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 68.8% and 6.3% of all recommendations. Check price target & stock forecast for Nice here>>> The ABR suggests buying Nice, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. In terms of earnings estimate revisions for Nice, the Zacks Consensus Estimate for the current year has increased 0% over the past month to $12.37. Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Nice. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for Nice may serve as a useful guide for investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nice (NICE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Sport
- Yahoo
Uncertainty surrounds Tanguy Ndombélé's OGC Nice future
Tanguy Ndombélé (28) looked like a player reborn at the start of last season. The Frenchman looked to have got his career back on track after joining OGC Nice on a free transfer, following the termination of his deal at Tottenham Hotspur. For a short time, there was even talk of a return to the France set-up, however, the injuries that stalled his progress in recent years returned around the turn of the calendar year. Suffering from a pubalgia issue, his last appearance in Ligue 1 dates back to the end of February, whilst the problem has severely limited his gametime. His last start dates back to mid-January. He has not even been included in a matchday squad since February. Advertisement Speaking to L'Équipe last month, Franck Haise cast doubt over Ndombélé's future. 'If I could be sure that he could be 100% operational for a season, I wouldn't ask the question (about his future), but that isn't the case,' he said. L'Équipe understands that the midfielder's future is still up in the air. With his contract up next summer, he must convince Nice's hierarchy to retain his place in the squad. Get French Football News understands that the Frenchman is still struggling with the issue and there is no guarantee that he will be operational come the start of the season, which for Nice starts early, as they contest the UEFA Champions League qualifiers. GFFN | Luke Entwistle
